The Scientific Challenge of Hepatitis C

This is the authors' abstract. We don't add key points for this paper.

The hepatitis C virus (HCV) infects some 170 million people worldwide--more than four times as many as HIV--and is causing rising rates of liver disease. Like HIV, it is a wily foe for researchers developing drugs and vaccines, because HCV also mutates rapidly, creating a swarm of different viruses in each infected person that can thwart antibodies easily. But progress is beginning to be made: Although to date no one has been able to grow HCV reliably in a laboratory culture of cells, on page 110, researchers describe a new system for culturing HCV9s RNA. And a study on page 107 offers one possible explanation for why some HCV strains are more resistant to interferon, the standard treatment for HCV, than others.